A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis

Cerdulatinib (DMVT-502) is a novel kinase inhibitor with demonstrated activity against JAK and spleen tyrosine kinase (Syk) (Coffey et al., 2014). Topical cerdulatinib is the first topical JAK/Syk inhibitor in development for the treatment of atopic dermatitis (AD). Preclinically, cerdulatinib gel (0.2% and 0.4%, representing 0.18% and 0.37% of free base, respectively) was shown to improve epidermal hyperplasia, inflammatory cell infiltration, and hyperkeratosis in an AD mouse model (McHale et al., 2018).

Source: Journal of Investigative Dermatology - January 22, 2021 Category: Dermatology Authors: Stephen C. Piscitelli, Ana B. Pavel, Kimberly McHale, John E. Jett, Jon Collins, Dawn Gillmor, Glenn Tabolt, Randall Li, Teresa Song, Ning Zhang, Anna M. Tallman, Emma Guttman-Yassky Tags: Letters to the Editor Source Type: research